Bergen, Norway, 9 August 2022- BerGenBio ASA (OSE:BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL inhibitors for severe
unmet medical needs, will be announcing its results for the second quarter and
half year 2022 on Tuesday 23 August 2022. The briefing will take place at 10:00
am CET at:
Carnegie AS, Fjordalleen 16, Aker Brygge, 5th Floor, Oslo
where BerGenBio's senior management team will provide an update on the
Company followed by a Q&A session. To attend in person please register by mail
to
ir@bergenbio.com

The presentation will webcast live and a link will be available at
www.bergenbio.com in the Investors/Financial Reports section and a recording
will be available shortly after the webcast has finished.

The second quarter and half year report and presentation will be made available
on the Company's website in the Investors/Financial Reports section from 7:00am
CET the same day.

-End-

Contacts

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com

Investor Relations / Media Relations

Graham Morrell

Graham.morrell@bergenbio.com

+1 781 686 9600

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate bemcentinib a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and COVID-19.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit?www.bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.